LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

E3 ubiquitin ligase MID1 ubiquitinates and degrades type‐I interferon receptor 2

Type I interferon (IFN‐I) is a common biological molecule used for the treatment of viral diseases. However, the clinical antiviral efficacy of IFN‐I needs to be greatly improved. In this… Click to show full abstract

Type I interferon (IFN‐I) is a common biological molecule used for the treatment of viral diseases. However, the clinical antiviral efficacy of IFN‐I needs to be greatly improved. In this study, IFN‐I receptor 2 (IFNAR2) was revealed to undergo degradation at the protein level in cells treated with IFN‐I for long periods of time. Further studies found a physical interaction between the E3 ubiquitin ligase midline‐1 (MID1) and IFNAR2. As a consequence, MID1 induced both K48‐ and K63‐linked polyubiquitination of IFNAR2, which promoted IFNAR2 protein degradation in a lysosome‐dependent manner. Conversely, knockdown of MID1 largely restricted IFN‐I‐induced degradation of IFNAR2. Importantly, MID1 regulated the strength of IFN‐I signalling and IFN‐I‐induced antiviral activity. These findings reveal a regulatory mechanism of IFNAR2 ubiquitination and protein stability in IFN‐I signalling, which could provide a potential target for improving the antiviral efficacy of IFN‐I.

Keywords: ubiquitin ligase; ifn; mid1; receptor; type interferon

Journal Title: Immunology
Year Published: 2022

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.